Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from rat) |
Target | β7 subunit of α4β7 and αEβ7 integrin heterodimers |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6396H9874N1702O2010S42 |
Molar mass | 144119.77 g·mol−1 |
![]() ![]() |
Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn's disease. It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7. [1] Etrolizumab was developed by Genentech [2] [3] by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells. [4]
As of 2016, it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's. [2] [5] [6] According to data of one meta-analysis efficacy of Etrolizumab is comparable with conventional therapies such as Infliximab with less adverse events [7]
Phase III clinical trials produced mixed results; and, on October 14, 2020, Hoffmann-La Roche, the parent company of Genentech, abandoned further efforts to develop etrolizumab for ulcerative colitis, but continued development for Crohn's disease, [8] until disappointing trial results led to this being abandoned too in Feb 2022. [9]
{{
cite web}}
: CS1 maint: archived copy as title (
link)
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from rat) |
Target | β7 subunit of α4β7 and αEβ7 integrin heterodimers |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6396H9874N1702O2010S42 |
Molar mass | 144119.77 g·mol−1 |
![]() ![]() |
Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn's disease. It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7. [1] Etrolizumab was developed by Genentech [2] [3] by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells. [4]
As of 2016, it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's. [2] [5] [6] According to data of one meta-analysis efficacy of Etrolizumab is comparable with conventional therapies such as Infliximab with less adverse events [7]
Phase III clinical trials produced mixed results; and, on October 14, 2020, Hoffmann-La Roche, the parent company of Genentech, abandoned further efforts to develop etrolizumab for ulcerative colitis, but continued development for Crohn's disease, [8] until disappointing trial results led to this being abandoned too in Feb 2022. [9]
{{
cite web}}
: CS1 maint: archived copy as title (
link)